Last reviewed · How we verify
Comparator: Aprepitant
Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent nausea and vomiting.
Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy, Post-operative nausea and vomiting (PONV) prevention.
At a glance
| Generic name | Comparator: Aprepitant |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Neurokinin-1 (NK1) receptor antagonist |
| Target | NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aprepitant crosses the blood-brain barrier and selectively antagonizes NK1 receptors, which are involved in the emetic pathway. By blocking substance P, a key neurotransmitter in nausea and vomiting, it provides antiemetic effects particularly effective against chemotherapy-induced nausea and vomiting (CINV). It is often used as part of a multimodal antiemetic regimen alongside 5-HT3 antagonists and corticosteroids.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
- Post-operative nausea and vomiting (PONV) prevention
Common side effects
- Fatigue
- Constipation
- Diarrhea
- Headache
- Hiccups
Key clinical trials
- Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study (PHASE3)
- Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) (PHASE2)
- A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) (PHASE3)
- A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219) (PHASE2)
- A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) (PHASE1)
- Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031) (PHASE3)
- Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) (PHASE3)
- Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Aprepitant CI brief — competitive landscape report
- Comparator: Aprepitant updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI